- About Us
- Contact Us
AIM Rule 26 Information
The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.
Please click below for a description of the business.
Country of Incorporation and Main Country of Operation
Country of Incorporation: England and Wales
Company Registration Number: 3929567
Main Country of Operation: France
50 Broadway, London SW1H 0RG, UK
Click on the link above for the Immupharma plc 2014 Annual Report.
Please note the file may take a few minutes to open.
It is recommended you save the report on your hard drive; right click on the photo and choose "Save As" and then save it on your computer before you open it.
Latest Interim Report
30 April 2015
Notice of Annual General Meeting: 29 May 2015
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM: IMM) (the "Company") the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2014 has been posted to shareholders.
The annual report is available, in electronic form, for download on the Company's website www.immupharma.org
The Company's Annual General Meeting will be held on 29 May 2015 at 11:00am at the offices of Bircham Dyson Bell LLP, 50 Broadway, London SW1H 0BL.
Nominated Advisor & Broker
Northland Capital Partners Ltd, 60 Gresham St, London EC2V 7BB
Tel +44 20 3861 6625
Tel +44 20 3861 6625
Public and Investor Relations
Bircham Dyson Bell, 50 Broadway, London SW1H 0BL, UK
Nexia Smith & Williamson Chartered Accountants
25 Moorgate London EC2R 6AY, UK
Royal Bank of Scotland plc
62/63 Threadneedle Street, London EC2R 8LA, UK
Computershare Investor Services PLC, PO Box 82, The Pavilions, Bridgewater Road, Bristol, BS99 7NH, UK
Current Constitutional Documents
Please click below for details of current constitutional documents.
For all notifications, please check the Regulatory News section.
Details of Any Other Exchanges or Trading Platforms
The Company's shares are also traded in Germany. 'Tradegate' which is an open market listing on the Berlin Exchange and the 'third segment' of the Stuttgart Stock Exchange.
Number of Securities In Issue and Significant Shareholders
ImmuPharma has 132,522,985 ordinary shares of 10p each in issue, each of which entitles the holder to cast one vote in general meetings. The company does not hold any Ordinary Shares in treasury. The Company is not aware of any interest of 3% or more in the share capital of the Company other than the persons noted below.
As far as the Company is aware, the percentage of ImmuPharma’s issued share capital that is not in public hands is just over 22%. This percentage comprises the holdings of Directors only.
Details of any restrictions on the transfer of securities
There are no restrictions on the transfer of securities.
Circulars, Proxy Forms and Admission Document
Please click on the link below to access the Company's Proxy Form
IMM Proxy Form: Annual General Meeting to be held on 26 May 2016
Please click on the link below to access the Company's circulars
IMM Circular February 2016 Fundrasing
Please click on the link below to access the Company’s Proxy Forms
IMM Proxy Form February 2016 Fundraising
Please click on the link below to access the Company's Admission Document (January 2006).
ImmuPharma Admission Document
Special rules apply when US persons (as defined in the United States securities laws) access this website. For US regulatory reasons, US residents and other US persons who reside outside the United States are not permitted to access this website. The company is not offering any securities or services in the United States or to residents of the United States through this website or otherwise. Please refer to our Disclaimer.
Last Updated: 23/03/2017